NGI-1

Research use only, not for human use.

NGI-1 is a a cell-permeable inhibitor of oligosaccharyltransferase (OST).can effectively reduce virus infectivity without affecting cell viability.

NGI-1 is a a cell-permeable inhibitor of oligosaccharyltransferase (OST).can effectively reduce virus infectivity without affecting cell viability.

NGI-1 inhibits the glycosylation of LASV GP mediated by STT3A-OST (in STT3B- and MAGT1-TUSC3- cells) or STT3B-OST (in STT3A- cells) and impaires its proteolytic cleavage in a dose-dependent manner.NGI-1 blocks EGFR N-linked glycosylation in lung adenocarcinoma cells as assessed. In controls EGFR is biotinylated, consistent with its plasma membrane expression, but in NGI-1 treated cells the EGFR is predominantly found in the non-biotinylated intracellular fraction suggesting a change in cellular localization. Western Blot Analysis Cell Line:STT3A-, STT3B- and MAGT1-TUSC3- cellsConcentration:1, 2, 5 μM Incubation Time:36 hours Result:Inhibited the glycosylation of LASV GP mediated by STT3A-OST (in STT3B- and MAGT1-TUSC3- cells) or STT3B-OST (in STT3A- cells) and impaired its proteolytic cleavage in a dose-dependent manner.

——

ML414

Others

Other Targets

oligosaccharyltransferase

——

——

790702-57-7

394.51

C17H22N4O3S2

>98% (HPLC)

DMSO:160 mg/mL (405.57 mM)

CN(C)S(=O)(=O)c1ccc(N2CCCC2)c(c1)C(=O)Nc1ncc(C)s1

5-(dimethylsulfamoyl)-N-(5-methyl-13-thiazol-2-yl)-2-(pyrrolidin-1-yl)benzamide

(-20℃)

With Ice Pack

≥ 2 years